Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE
Durvalumab联合每周一次的卡铂/紫杉醇作为一线治疗方案，用于不适合接受顺铂类化疗的复发性和/或转移性头颈部鳞状细胞癌（HNSCC）患者：多中心前瞻性研究FRAIL-IMMUNE的结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106946
Fayette, J; Cropet, C; Toullec, C; Burgy, M; Bruyas, A; Sire, C; Lagrange, A; Clatot, F; Vinches, M; Iacob, M; Martin, L; Kaminsky, M-C; Vansteene, D; Salas, S; Champagnac, A; Saintigny, P; Gautier, J; Pérol, D; Bourhis, J
